Biophytis Showcases RuvembriTM's Potential in Duchenne Muscular Dystrophy Treatment

Biophytis SA disclosed details about its clinical trials of RuvembriTM during the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando. These trials, specifically the SARA-INT and COVA involving sarcopenic patients and severe COVID-19 patients respectively, highlighted RuvembriTM's effectiveness and safety. This promising data supports its potential usage against Duchenne Muscular Dystrophy (DMD), a severe neuromuscular disorder.

With orphan drug designation already secured in both Europe and the USA, Biophytis is planning to initiate a phase 1-2 clinical trial targeting non-ambulatory DMD patients showing respiratory failure. CEO Stanislas Veillet emphasized the urgent need for effective treatments for DMD, highlighting the immense market opportunity and the anticipatory growth in demand by 2029.

The company, operating from Paris and Cambridge, is dedicated to developing therapies for ailments linked with aging. RuvembriTM, their leading candidate, has shown encouraging results in conditions like sarcopenia and severe COVID-19, and is now being tailored for DMD's pediatric cases.